Fibroblast growth factor 23 is associated with proteinuria and smoking in chronic kidney disease: An analysis of the MASTERPLAN cohort

BMC Nephrology

Table 3 Model 2. Relation of lnFGF23 in the full adjusted model with cardiovascular and renal risk factors

Variable	B	Standard error	Beta	p-value
eGFR (MDRD, ml/min/1.73 m ² )	-0.022	0.003	-034	< 0.001
Phosphate (mmol/l)	0.297	0.131	0.082	0.024
lnPTH (pmol/l)	0.244	0.047	0.196	< 0.001
Calcium (mmol/l)	0.393	0.220	0.062	0.075
Proteinuria (gram/24 hours)	0.064	0.021	0.113	0.002
Male	-0.094	0.071	-0.048	0.183
Smoking	0.313	0.073	0.148	< 0.001
BMI	0.003	0.007	0.017	0.638
Diabetes Mellitus	0.159	0.075	0.075	0.035
History CVD	0.224	0.071	0.113	0.002
Age (year)	0.001	0.003	0.006	0.868
Systolic blood pressure (mmHg)	-0.001	0.002	-0.02	0.586
Total cholesterol (mmol/l)	0.006	0.031	0.007	0.848
Active vitamin D use	0.096	0.079	0.044	0.223

Model 2: multivariable analyses of relation of lnFGF23 with Framingham risk factors (model 1) and renal risk factors. B reflects change in lnFGF23 per unit change in the variable. For dichotomous variables (sex, smoking, diabetes, and history of CVD) B reflects lnFGF23 change in the presence of the depicted variable. Beta is the standardized B to compare influence on lnFGF23 between variables.
eGFR: estimated glomerular filtration rate; MDRD: four-point MDRD-formula; BMI: Body mass index; CVD: cardiovascular disease